vs
Side-by-side financial comparison of Canadian Solar Inc. (CSIQ) and GE HealthCare (GEHC). Click either name above to swap in a different company.
GE HealthCare is the larger business by last-quarter revenue ($5.7B vs $4.5B, roughly 1.3× Canadian Solar Inc.). GE HealthCare runs the higher net margin — 10.3% vs 1.3%, a 9.0% gap on every dollar of revenue.
Canadian Solar Inc. is a global renewable energy company. Headquartered in Kitchener, Ontario, the company manufactures solar PV modules, provides battery energy storage solutions and develops utility-scale solar power and battery energy storage projects.
GE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures...
CSIQ vs GEHC — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.5B | $5.7B |
| Net Profit | $57.6M | $588.0M |
| Gross Margin | 17.5% | 39.7% |
| Operating Margin | 2.2% | 14.5% |
| Net Margin | 1.3% | 10.3% |
| Revenue YoY | — | 7.1% |
| Net Profit YoY | — | -18.4% |
| EPS (diluted) | — | $1.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $5.7B | ||
| Q3 25 | $4.5B | $5.1B | ||
| Q2 25 | $3.0B | $5.0B | ||
| Q1 25 | $1.3B | $4.8B | ||
| Q4 24 | — | $5.3B | ||
| Q3 24 | $5.9B | $4.9B | ||
| Q2 24 | $4.1B | $4.8B | ||
| Q1 24 | — | $4.7B |
| Q4 25 | — | $588.0M | ||
| Q3 25 | $57.6M | $446.0M | ||
| Q2 25 | $63.6M | $486.0M | ||
| Q1 25 | $36.2M | $564.0M | ||
| Q4 24 | — | $721.0M | ||
| Q3 24 | $366.8M | $470.0M | ||
| Q2 24 | $304.4M | $428.0M | ||
| Q1 24 | — | $374.0M |
| Q4 25 | — | 39.7% | ||
| Q3 25 | 17.5% | 38.7% | ||
| Q2 25 | 18.0% | 39.6% | ||
| Q1 25 | 19.0% | 42.1% | ||
| Q4 24 | — | 42.8% | ||
| Q3 24 | 18.0% | 41.7% | ||
| Q2 24 | 18.7% | 41.4% | ||
| Q1 24 | — | 40.9% |
| Q4 25 | — | 14.5% | ||
| Q3 25 | 2.2% | 12.7% | ||
| Q2 25 | 3.3% | 13.1% | ||
| Q1 25 | 3.7% | 13.2% | ||
| Q4 24 | — | 15.1% | ||
| Q3 24 | 7.7% | 13.9% | ||
| Q2 24 | 9.1% | 12.6% | ||
| Q1 24 | — | 11.6% |
| Q4 25 | — | 10.3% | ||
| Q3 25 | 1.3% | 8.7% | ||
| Q2 25 | 2.1% | 9.7% | ||
| Q1 25 | 2.7% | 11.8% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | 6.2% | 9.7% | ||
| Q2 24 | 7.5% | 8.8% | ||
| Q1 24 | — | 8.0% |
| Q4 25 | — | $1.28 | ||
| Q3 25 | — | $0.98 | ||
| Q2 25 | — | $1.06 | ||
| Q1 25 | — | $1.23 | ||
| Q4 24 | — | $1.58 | ||
| Q3 24 | — | $1.02 | ||
| Q2 24 | — | $0.93 | ||
| Q1 24 | — | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $4.5B |
| Total DebtLower is stronger | — | $10.0B |
| Stockholders' EquityBook value | $3.9B | $10.4B |
| Total Assets | $13.5B | $36.9B |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.5B | ||
| Q3 25 | $1.7B | $4.0B | ||
| Q2 25 | $1.7B | $3.7B | ||
| Q1 25 | $1.7B | $2.5B | ||
| Q4 24 | — | $2.9B | ||
| Q3 24 | $1.9B | $3.5B | ||
| Q2 24 | $1.9B | $2.0B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | — | $10.0B | ||
| Q3 25 | — | $10.3B | ||
| Q2 25 | — | $10.3B | ||
| Q1 25 | — | $8.8B | ||
| Q4 24 | — | $9.0B | ||
| Q3 24 | — | $10.3B | ||
| Q2 24 | — | $9.2B | ||
| Q1 24 | — | $9.3B |
| Q4 25 | — | $10.4B | ||
| Q3 25 | $3.9B | $10.0B | ||
| Q2 25 | $3.9B | $9.7B | ||
| Q1 25 | $3.9B | $9.2B | ||
| Q4 24 | — | $8.4B | ||
| Q3 24 | $3.7B | $8.3B | ||
| Q2 24 | $3.7B | $7.8B | ||
| Q1 24 | — | $7.4B |
| Q4 25 | — | $36.9B | ||
| Q3 25 | $13.5B | $36.1B | ||
| Q2 25 | $13.5B | $35.5B | ||
| Q1 25 | $13.5B | $33.6B | ||
| Q4 24 | — | $33.1B | ||
| Q3 24 | $11.9B | $33.9B | ||
| Q2 24 | $11.9B | $31.9B | ||
| Q1 24 | — | $32.2B |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | — | 0.95× | ||
| Q4 24 | — | 1.06× | ||
| Q3 24 | — | 1.24× | ||
| Q2 24 | — | 1.18× | ||
| Q1 24 | — | 1.25× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-187.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | -3.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $-187.7M | — | ||
| Q2 25 | — | $94.0M | ||
| Q1 25 | — | $250.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-119.0M | ||
| Q1 24 | — | $419.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $8.0M | ||
| Q1 25 | — | $98.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-183.0M | ||
| Q1 24 | — | $274.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.8% | ||
| Q1 24 | — | 5.9% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | 3.1% |
| Q4 25 | — | — | ||
| Q3 25 | -3.26× | — | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | 0.44× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.28× | ||
| Q1 24 | — | 1.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSIQ
Segment breakdown not available.
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
